
Danaher, Vertex Pharmaceuticals, and Moderna are the three Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks are shares of publicly traded companies that research, develop, and commercialize biological products and technologies—such as drugs, gene therapies, diagnostics, and biologics. For investors they can offer substantial growth upside but also high volatility and binary risk, because company value often hinges on clinical-trial results, regulatory approvals, patents, and milestone-based financing rather than steady revenues. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.
Danaher (DHR)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
Read Our Latest Research Report on VRTX
Moderna (MRNA)
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Read Our Latest Research Report on MRNA
Featured Articles
- MarketBeat’s Top Five Stocks to Own in November 2025
 - Freshpet Insiders Called the Bottom: Now It’s Time to Buy
 - Ford and GM Stocks Jump—Is the Auto Rebound Real?
 - Q3 Telecom Wars: How AT&T, TMUS and VZ Stack Up After the Results
 - Boeing Closes in on Airbus With Best Delivery Quarter Since 2018
 - Put It on My Card: Why Luxury Brands and Payments Firms Pair Well
 
